Atnaujinkite slapukų nuostatas

El. knyga: Anticancer Agents from Natural Products

Edited by (Retired from the National Cancer Institute, Frederick, Maryland, USA), Edited by (Virginia Polytechnic Institute & State University, Blacksburg, USA), Edited by (Retired from the National Cancer Institute, Frederick, Maryland, USA)
  • Formatas: 767 pages
  • Išleidimo metai: 10-Oct-2011
  • Leidėjas: CRC Press Inc
  • Kalba: eng
  • ISBN-13: 9781040204252
Kitos knygos pagal šią temą:
  • Formatas: 767 pages
  • Išleidimo metai: 10-Oct-2011
  • Leidėjas: CRC Press Inc
  • Kalba: eng
  • ISBN-13: 9781040204252
Kitos knygos pagal šią temą:

DRM apribojimai

  • Kopijuoti:

    neleidžiama

  • Spausdinti:

    neleidžiama

  • El. knygos naudojimas:

    Skaitmeninių teisių valdymas (DRM)
    Leidykla pateikė šią knygą šifruota forma, o tai reiškia, kad norint ją atrakinti ir perskaityti reikia įdiegti nemokamą programinę įrangą. Norint skaityti šią el. knygą, turite susikurti Adobe ID . Daugiau informacijos  čia. El. knygą galima atsisiųsti į 6 įrenginius (vienas vartotojas su tuo pačiu Adobe ID).

    Reikalinga programinė įranga
    Norint skaityti šią el. knygą mobiliajame įrenginyje (telefone ar planšetiniame kompiuteryje), turite įdiegti šią nemokamą programėlę: PocketBook Reader (iOS / Android)

    Norint skaityti šią el. knygą asmeniniame arba „Mac“ kompiuteryje, Jums reikalinga  Adobe Digital Editions “ (tai nemokama programa, specialiai sukurta el. knygoms. Tai nėra tas pats, kas „Adobe Reader“, kurią tikriausiai jau turite savo kompiuteryje.)

    Negalite skaityti šios el. knygos naudodami „Amazon Kindle“.

"The search for new lead compounds is a crucial element of modern pharmaceutical research. Natural products provided the only source of pharmaceuticals for thousands of years, and natural products have made enormous contributions to human health through compounds such as quinine, morphine, aspirin (a natural product analog), digitoxin, and many others. The potential of natural products as anticancer agents was recognized in the 1950's by the U. S. National Cancer Institute (NCI) under the leadership of the late Dr. Jonathan Hartwell, and the NCI has since made major contributions to the discovery of new naturally occurring anticancer agents through its contract and grant support, including an important program of plant and marine collections. Many, although not all, of the compound classes described in the following pages owe their origin in whole or in part to NCI support. In spite of the success of the natural products approach to anticancer drug discovery, as exemplified by the following chapters, in recent years their importance as a source of molecular diversity for drug discovery research and development has been overshadowed by newer chemical approaches currently in favor. These approaches include chemical ones which make heavy use of combinatorial chemistry, and biological ones such as manipulation of biosynthetic pathways of microbial metabolites through combinatorial biosynthetic techniques. It is thus worthwhile to review briefly the major reasons why natural products are so important. First, there is a strong biological and ecological rationale for plants and marine invertebrates to produce novel bioactive secondary metabolites"--

"This book covers clinically used anticancer agents that are either natural products or are clearly derived from natural product leads. The second edition includes drugs that are currently in development. In addition, the text emphasizes the applications of synthetic and medicinal chemistry to the preparation of analogs with enhanced activities. Contributors also address the potential of novel drug discovery through the use of genome mining as well as the status of advanced development candidates. For each compound of class of compounds, the text provides information on the history, structure, mechanism of action, development, synthesis, medicinal chemistry, and clinical applications"--

"This book covers clinically used anticancer agents that are either natural products or are clearly derived from natural product leads. The second edition includes drugs that are currently in development. In addition, the text emphasizes the applicationsof synthetic and medicinal chemistry to the preparation of analogs with enhanced activities. Contributors also address the potential of novel drug discovery through the use of genome mining as well as the status of advanced development candidates. For each compound of class of compounds, the text provides information on the history, structure, mechanism of action, development, synthesis, medicinal chemistry, and clinical applications"--



Recenzijos

"maintains the extremely high standards of the first edition. Over the past few years, a comparatively large number of anticancer agents of natural product origin have been brought to the market, so this expanded and updated volume is of very high relevance to members of the biomedical research community. The authors and editors of this second edition deserve heartfelt congratulations for compiling such an informative and inspiring volume, which serves as a major addition to the natural products literature." A. Douglas Kinghorn, The Ohio State University, Columbus, in Journal of Natural Products

Praise for the Previous Edition

"The book brings home to us not only the amazing chemical complexity of the natural world but also the vast reservoir of potential new healing agents that yet remain to be tapped. This impressive work, which maintains a uniformly high standard throughout, will be of major benefit to a wide readership .It seems likely that it will remain the definitive work in its genre for many years to come." Chemistry World"Edited by leading scientists who have contributed enormously to natural product development and potential anticancer natural products, Anticancer Agents from Natural Products is a convenient summary of the current status of research and development of some of the most effective anticancer agents available today. It is an ideal foundation for scientist engaged in developing new and improved drugs based on natural sources." Memoriile Sectiilor Stintifice

PLANT PRODUCTS: Introduction. Camptothecin and its Analogs. Discovery
and Development of the Combretastatins. Homoharringtonine and Related
Compounds. Podophyllotoxins and Analogs. Taxol and Its Analogs. The Vinca
Alkaloids. MARINE PRODUCTS: The Bryostatins. The Cryptophycins. The
Discodermolides. The Dolastatins. Ecteinascidin-743. Aplidin. Kahalalide F.
Discovery of E7389. Synthetic Halichondrin Analog.HTI-286. Synthetic Analog
of Hemiasterlins. Salinosporamide etc. MICROBIAL PRODUCTS: The Actinomycins.
The Anthracyclines. Ansamitocins (Maytansanoids). Benzoquinone Ansamycins.
The Bleomycin Group. Biochemical Evaluation of CC1065 Analogs. Epothilone, A
Myxobacterial Metabolite. Enediynes Biosyntheses. The Mitomycins.
Staurosporines and Related Compounds. Potential for New Compounds from Gene
Analyses (Bacterial and Fungal). Environmental DNA. MISCELLANEOUS
DEVELOPMENTS: Combinatorial Biosynthesis. Developments and Future Trends.
Gordon M. Cragg obtained his undergraduate training in chemistry at Rhodes University, South Africa, and his D. Phil. (organic chemistry) from Oxford University. After two years of postdoctoral research at the University of California, Los Angeles, he returned to South Africa to join the Council for Scientific and Industrial Research. In 1966, he joined the Chemistry Department at the University of South Africa, and transferred to the University of Cape Town in 1972. In 1979, he returned to the US to join the Cancer Research Institute at Arizona State University working with Professor G. R. Pettit. In 1985, he moved to the National Cancer Institute (NCI), National Institutes of Health (NIH) in Bethesda, Maryland, and was appointed Chief of the NCI Natural Products Branch in 1989. He retired in December, 2004, and is currently serving as an NIH Special Volunteer. His major interests lie in the discovery of novel natural product agents for the treatment of cancer and AIDS, with an emphasis on multidisciplinary and international collaboration. He has given over 100 invited talks at conferences in many countries worldwide, and has been awarded NIH Merit Awards for his contributions to the development of the anticancer drug, Taxol (1991), leadership in establishing international collaborative research in biodiversity and natural products drug discovery (2004), and contributions to developing and teaching NIH technology transfer courses (2004). He was President of the American Society of Pharmacognosy in 1998-1999, was elected to Honorary Membership of the Society in 2003, and was named a Fellow of the Society in 2008. In November 2006 he was awarded the William L. Brown Award for Plant Genetic Resources by Missouri Botanical Garden which also named a recently discovered Madagascar plant in his honor, Ludia craggiana, and in April 2010 he was awarded an Honorary Doctorate of Science by his South African alma mater, Rhodes University.